Efficacy of Different Dietary Pattern in Long-term Weight Management (EDI-Weight)

A Multicenter Randomized Controlled Trial Evaluating the Efficacy of Different Dietary Pattern Management Programs in Long-term Weight Management

This study is a nationwide multi-center, long-term randomized controlled clinical trial, aiming to evaluate the effects of individualized dietary pattern management programs compared to traditional energy-restricted diets in weight management.

Study Overview

• Status: Not yet recruiting
• Conditions: Dietary Intervention; Obesity and Overweight
• Intervention / Treatment: Behavioral: Individualized dietary intervention; Behavioral: Traditional energy-restricted balanced diet

• Study Type: Interventional
• Enrollment (Estimated): 800
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jieli Lu, MD, PhD; Phone Number: +86-15921591766; Email: jielilu@hotmail.com

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200025
      • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female, aged 20-59 years
2. Obesity defined by BMI≥28 kg/m²;
3. With willingness to undergo dietary intervention for weight loss.

Exclusion Criteria:

1. BMI≥40 kg/m²;
2. Suffering from gastrointestinal diseases that affect food digestion and absorption (such as functional bowel disorders, etc.), or having a known history of food allergies, or having a history of previous gastrointestinal surgery that affects dietary intervention;
3. Suffering from diseases that affect body weight or glucose and lipid metabolism (such as uncontrolled hyponatremia, thyroid dysfunction, secondary hypertension, type 1 diabetes, Cushing's syndrome, etc.);
4. Currently undergoing pharmacological treatment that affects body weight or glucose and lipid metabolism (such as thyroid medications, corticosteroids, antidiabetic drugs, lipid-lowering drugs, diuretics, etc.);
5. Having been diagnosed with clinical cardiovascular disease (coronary heart disease, stroke, heart failure, etc.) or malignancy;
6. Suffering from severe liver or kidney disease (alanine aminotransferase or serum creatinine levels exceeding 2 times the upper limit of normal);
7. Pregnant, breastfeeding, or women of childbearing potential who are not using contraception;
8. Any condition deemed by the investigator to affect study compliance;
9. Currently participating in another interventional study or having participated in another drug clinical trial within the past 3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Individualized dietary intervention; Individualized dietary intervention guided by refined obesity phenotyping and based on digital management tools was adopted. Dietitians will use the decision tree algorithm of the digital management tool to first set the macronutrient ratios and dietary pattern recommendations based on ①metabolic health status and ②body composition characteristics, then set the eating rhythm recommendations based on ③emotional characteristics and ④individual behavioral characteristics，and then set the food recommendations based on ⑤dietary preferences.	Behavioral: Individualized dietary intervention; The participants will take a individualized dietary intervention guided by refined obesity phenotyping and based on digital management tools. Dietitians will use the decision tree algorithm of the digital management tool to first set the macronutrient ratios and dietary pattern recommendations based on ①metabolic health status and ②body composition characteristics, then set the eating rhythm recommendations based on ③emotional characteristics and ④individual behavioral characteristics，and then set the food recommendations based on ⑤dietary preferences.
Experimental: Traditional energy-restricted balanced diet; A traditional energy-restricted balanced diet based on the resting energy expenditure measured at baseline for each participant. A daily caloric deficit of 500 kcal was set for each individual. Dietitians provided dietary guidance plans and recommended sample menus in accordance with the traditional general dietary recommendations from the "Dietary Reference Intakes for Chinese Residents." The overall dietary principles emphasized a diet rich in whole grains, low in fat, with ample vegetables and fruits, and avoiding added sugars.	Behavioral: Traditional energy-restricted balanced diet; The participants will take a traditional energy-restricted balanced diet based on the resting energy expenditure measured at baseline for each participant. A daily caloric deficit of 500 kcal was set for each individual. Dietitians provided dietary guidance plans and recommended sample menus in accordance with the traditional general dietary recommendations from the "Dietary Reference Intakes for Chinese Residents." The overall dietary principles emphasized a diet rich in whole grains, low in fat, with ample vegetables and fruits, and avoiding added sugars.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of body weight loss from baseline to 12 months	Body weight will be measured in kilograms using a standardized calibrated scale. Percentage of body weight loss will be calculated as [(baseline body weight - body weight at 12 months) / baseline body weight] × 100. Higher values indicate greater weight loss. The between-group difference will be evaluated.	Baseline and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants achieving more than 5% body weight loss at 12 months	A participant will be classified as achieving more than 5% body weight loss if [(baseline body weight - body weight at 12 months) / baseline body weight] × 100 is greater than 5. The percentage of evaluable participants meeting this criterion will be compared between the two study groups.	12 months
Change in body mass index from baseline to 12 months	Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m². The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in waist circumference from baseline to 12 months	Waist circumference will be measured in centimeters using a standardized measurement protocol. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in body fat percentage from baseline to 12 months	Body fat percentage will be assessed by dual-energy X-ray absorptiometry and reported as a percentage. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in total lean body mass from baseline to 12 months	Total lean body mass will be assessed by dual-energy X-ray absorptiometry and reported in kilograms. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in liver proton density fat fraction from baseline to 12 months	Liver proton density fat fraction will be quantified by abdominal magnetic resonance imaging using the mDixon-Quant technique and reported as a percentage. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in fasting blood glucose concentration from baseline to 12 months	Fasting blood glucose concentration will be measured by a local clinical laboratory and reported in mmol/L. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in total cholesterol concentration from baseline to 12 months	Serum total cholesterol concentration will be measured by a clinical laboratory and reported in mmol/L. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in triglyceride concentration from baseline to 12 months	Serum triglyceride concentration will be measured by a clinical laboratory and reported in mmol/L. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in low-density lipoprotein cholesterol concentration from baseline to 12 months	Serum low-density lipoprotein cholesterol concentration will be measured by a clinical laboratory and reported in mmol/L. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in high-density lipoprotein cholesterol concentration from baseline to 12 months	Serum high-density lipoprotein cholesterol concentration will be measured by a clinical laboratory and reported in mmol/L. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in systolic blood pressure from baseline to 12 months	Seated systolic blood pressure will be measured three times using a standardized procedure. The mean of the three readings will be reported in mmHg, and the change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in diastolic blood pressure from baseline to 12 months	Seated diastolic blood pressure will be measured three times using a standardized procedure. The mean of the three readings will be reported in mmHg, and the change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in total physical activity assessed by the International Physical Activity Questionnaire from baseline to 12 months	Total physical activity will be calculated from self-reported walking, moderate-intensity activity, and vigorous-intensity activity using the International Physical Activity Questionnaire scoring method and expressed in MET-minutes/week. Higher values indicate greater physical activity.	Baseline and 12 months
Change in sleep quality assessed by the Pittsburgh Sleep Quality Index from baseline to 12 months	Sleep quality will be assessed using the Pittsburgh Sleep Quality Index global score, ranging from 0 to 21. Higher scores indicate poorer sleep quality. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in health-related quality of life assessed by the EQ-5D-5L index from baseline to 12 months	Health-related quality of life will be assessed using the EQ-5D-5L index value calculated with the applicable Chinese value set. Higher index values indicate better health status. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in self-rated health assessed by the EQ visual analogue scale from baseline to 12 months	Self-rated health will be assessed using the EQ visual analogue scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in emotional eating assessed by the Three-Factor Eating Questionnaire-R21 from baseline to 12 months	Emotional eating will be assessed using the emotional eating subscale of the Three-Factor Eating Questionnaire-R21 and scored according to the standardized scoring algorithm. Higher scores indicate greater emotional eating. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in cognitive restraint assessed by the Three-Factor Eating Questionnaire-R21 from baseline to 12 months	Cognitive restraint will be assessed using the cognitive restraint subscale of the Three-Factor Eating Questionnaire-R21 and scored according to the standardized scoring algorithm. Higher scores indicate greater cognitive restraint. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in uncontrolled eating assessed by the Three-Factor Eating Questionnaire-R21 from baseline to 12 months	Uncontrolled eating will be assessed using the uncontrolled eating subscale of the Three-Factor Eating Questionnaire-R21 and scored according to the standardized scoring algorithm. Higher scores indicate greater uncontrolled eating. The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in hunger assessed by a visual analogue scale from baseline to 12 months	Hunger will be assessed using a 100-mm visual analogue scale ranging from 0 (not hungry at all) to 100 (extremely hungry). The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in fullness assessed by a visual analogue scale from baseline to 12 months	Fullness will be assessed using a 100-mm visual analogue scale ranging from 0 (not full at all) to 100 (extremely full). The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in desire to eat assessed by a visual analogue scale from baseline to 12 months	Desire to eat will be assessed using a 100-mm visual analogue scale ranging from 0 (no desire to eat) to 100 (very strong desire to eat). The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Change in prospective food consumption assessed by a visual analogue scale from baseline to 12 months	Prospective food consumption will be assessed using a 100-mm visual analogue scale ranging from 0 (could eat nothing) to 100 (could eat a large amount). The change from baseline to 12 months will be compared between the two study groups.	Baseline and 12 months
Dietary-recording adherence during the 12-month intervention	Dietary-recording adherence will be calculated as the number of completed 24-hour dietary records divided by the number of scheduled dietary records, multiplied by 100. Participants are scheduled to complete three 24-hour dietary records per week during months 0-3 and three 24-hour dietary records per month during months 4-12.	From baseline through 12 months
Change in body weight from 12 months to 24 months	Body weight will be measured in kilograms using a standardized calibrated scale. The change from 12 months to 24 months will be used to assess weight regain after the 12-month intervention and compared between the two study groups.	12 months and 24 months
Change in body mass index from 12 months to 24 months	Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m². The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in waist circumference from 12 months to 24 months	Waist circumference will be measured in centimeters using a standardized measurement protocol. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in body fat percentage from 12 months to 24 months	Body fat percentage will be assessed by dual-energy X-ray absorptiometry and reported as a percentage. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in total lean body mass from 12 months to 24 months	Total lean body mass will be assessed by dual-energy X-ray absorptiometry and reported in kilograms. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in liver proton density fat fraction from 12 months to 24 months	Liver proton density fat fraction will be quantified by abdominal magnetic resonance imaging using the mDixon-Quant technique and reported as a percentage. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in fasting blood glucose concentration from 12 months to 24 months	Fasting blood glucose concentration will be measured by a local clinical laboratory and reported in mmol/L. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in total cholesterol concentration from 12 months to 24 months	Fasting serum total cholesterol concentration will be measured by the central laboratory and reported in mmol/L. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in triglyceride concentration from 12 months to 24 months	Fasting serum triglyceride concentration will be measured by the central laboratory and reported in mmol/L. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in low-density lipoprotein cholesterol concentration from 12 months to 24 months	Fasting serum low-density lipoprotein cholesterol concentration will be measured by the central laboratory and reported in mmol/L. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in high-density lipoprotein cholesterol concentration from 12 months to 24 months	Fasting serum high-density lipoprotein cholesterol concentration will be measured by the central laboratory and reported in mmol/L. The change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in systolic blood pressure from 12 months to 24 months	Seated systolic blood pressure will be measured three times using a standardized procedure. The mean of the three readings will be reported in mmHg, and the change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months
Change in diastolic blood pressure from 12 months to 24 months	Seated diastolic blood pressure will be measured three times using a standardized procedure. The mean of the three readings will be reported in mmHg, and the change from 12 months to 24 months will be compared between the two study groups.	12 months and 24 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with diet-intervention-related adverse events	Diet-intervention-related adverse events include food allergy, fatigue, dizziness, diarrhea, constipation, acid reflux, hypoglycemia, and other discomfort considered related to the dietary intervention. The number of participants experiencing at least one such event will be reported.	From the first dietary intervention through 24 months
Number of participants with serious adverse events	A serious adverse event is an event that results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, results in persistent or significant disability, causes a congenital anomaly, or is another medically important event. The number of participants experiencing at least one serious adverse event will be reported.	From enrollment through 24 months

Collaborators and Investigators

• Sponsor: Guang Ning

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): May 20, 2028
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: May 23, 2025
• First Submitted That Met QC Criteria: August 14, 2026
• First Posted (Actual): August 19, 2026

Study Record Updates

• Last Update Posted (Actual): August 19, 2026
• Last Update Submitted That Met QC Criteria: August 14, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Keywords: obesity; weight; dietary
• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Body Weight
• Other Study ID Numbers: CCEMD-20250510

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No